In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus

Revista Espanola de Quimioterapia

Volumn 19, Issue 3, 2006, Pages 252-257

  Sahuquillo Arce, J M ^a   Colombo Gainza, E ^a   Gil Brusola, A ^a   Ortiz Estevez R ^a   Canton E ^a   Gobernado, M ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Fosfomycin; Oxazolidinone; Synergism

Indexed keywords

DOXYCYCLINE FOSFATEX; FOSFOMYCIN; LEVOFLOXACIN; LINEZOLID; RIFAMPICIN; VANCOMYCIN;

ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DOXYCYCLINE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FOSFOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; OXAZOLIDINONES; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 33750911766     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Clement, D., Markham, A. Linezolid. Drugs 2000; 59: 815-827.
2. Diekema, D.J., Jones, R.N. Oxazolidinones: A review. Drugs 2000; 59: 7-16.
3. Gemmell, C.G. Susceptibility of a variety of clinical isolates to linezolid: A European inter-country comparison. J Antimicrob Chemother 2001; 48: 47-52.
4. Jacqueline, C., Caillon, J., Le Mabecque, V. et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003; 51: 857-864.
5. Shinabarger, D.L., Marotti, K.R., Murray, R.W. et al. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions. Antimicrobial Agents Chemother 1997; 41: 2132-2136.
6. Swaney, S.M., Aoki, H., Anoza, M.C. et al. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrobial Agents Chemother 1998; 42: 3251-3255.
7. Dresser, L.D., Ryback, M.J. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 1998; 18: 456-462.
8. Gee, T., Ellis, R., Marshal, G. et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrobial Agents Chemother 2001; 45: 1843-1846.
9. Bain, K.T., Wittbrodt, E.T. Linezolid for the treatment of resistant Gram-positive cocci. Ann Pharmacother 2001; 35: 556-575.
10. Carmona, P., Romá, E., Monte, E. et al. Papel de linezolid en terapéutica antimicrobiana. Enferm Infecc Microbiol Clin 2003; 21: 30-41.
11. Kutscha-Lissberg, F., Hebler, U., Muhr, G. et al. Linezolid penetration into bone and joint tissues infected with methicillin-resistant Staphylococci. Antimicrob Agents Chemother 2003; 47: 3964-3966.
12. Rana, B., Butcher, I., Grigorisi, P. et al. Linezolid penetration into osteo-articular tissues. J Antimicob Chemother 2002; 50: 747-750.
13. Rubinstein, E., Cammarata, S.K., Oliphant, T.H. y cols. Linezolid Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized doble-blind, multicenter study. Clin Infect Dis 2001; 32: 402-412.
14. Stevens, D.L., Smith, L.G., Bruss, J.B. et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-doxacillin for treatment of complicated skin and soft tissue infections. Antimicrobial Agents Chemother 2000; 44: 3408-3413.
15. Chien, J.W., Kucia, M.L., Salata, R.A. Use of linezolid, an oxazolidinone, in the treatment of miltidrug-resistant Gram-positive bacterial infections. Clin Infect Dis 2000; 30: 146-151.
16. Cisterna, R. Conclusiones y perspectivas en la utilización del linezolid. Rev Esp Quimioterap 2002; 15 (Suppl. 3): 107-113.
17. Perry, C.M., Jarvis, B. Linezolid: A review of its use in the management of serious Gram-positive infections. Drugs 2001; 61: 525-551.
18. Soriano, A., Jurado, A., Marco, F. et al. Actividad in vitro de linezolid, moxifloxacino, levofloxacino, clindamicina y rifampicina solos o en combinación, frente a Staphylococcus aureus y Staphylococcus epidermidis. Rev Esp Quimioterap 2005; 18: 168-172.
19. Bayer, A.S., Morrison, J.O. Disparity between time-kill and checker-board methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and resistant Staphylococcus aureus. Antimicrob Agents Chemother 1984; 26: 220-223.
20. European Committee on Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infections Diseases (ESCMID). Linezolid breakpoints. Clin Microbiol Infect 2001; 7: 283-284.
21. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically; approved standard. Sixth ed. M7-A6 NCCLS, Wayne, PA, 2003.
22. Eliopoulos, G.M., Moellering, R. Antimicrobial combinations. In: Victor Lorian (Ed.). Antibiotics in Laboratory Medicine, fourth ed. Williams and Wilkins, Baltimore 1996; 330-396.
23. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. Document M26-A. NCCLS, Wayne, PA, USA 1999.
24. Sweeney, M.T., Zurenko, G.E. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected Gram-negative organisms. Antimicrobial Agents Chemother 2003; 47: 1902-1906.
25. Grohs, P., Kitzis, M.D., Gutmann, L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 418-420.
26. Grif, K., Dierich, M.P., Pfaller, K. et al. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 2001; 48: 209-217.
27. Dailey, C.F., Pagano, P.J., Buchanan, L.V. et al. Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrobl Agents Chemother 2003; 47: 2655-2658.
28. Gander, S., Hayward, K., Finch, R. An investigation on the antimicrobial effect of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model. J Antimicrob Chemother 2002; 49: 301-308.
29. Gobernado, M. Fosfomicina. Rev Esp Quimioterap 2003; 16: 15-40.